Dexcom

DXCM · NASDAQ

$85.74−$0.24 (−0.28%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $85.98

Latest news

Press releaseOct 14, 5:10 PM ETBusiness Wire
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
Press releaseOct 7, 8:30 AM ETBusiness Wire
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
Press releaseOct 6, 9:00 AM ETBusiness Wire
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
NewsOct 5, 3:00 PM ETPiero Cingari
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
NewsSep 28, 8:46 AM ETGianni di Poce
The Insider Report: The Leaders Have Taken Off
Press releaseSep 28, 2:00 AM ETBusiness Wire
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
Press releaseSep 14, 4:30 PM ETBusiness Wire
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Press releaseSep 10, 4:15 PM ETBusiness Wire
Dexcom Appoints Glenn Boehnlein to Board of Directors
Press releaseSep 7, 3:27 PM ETPRNewswire
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Press releaseSep 1, 8:30 AM ETBusiness Wire
Dexcom Announces Upcoming Conference Presentation
NewsAug 26, 9:36 AM ETVandana Singh
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
NewsJul 31, 1:42 PM ETPiero Cingari
Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 Billion
NewsJul 31, 10:05 AM ETAvi Kapoor
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
NewsJul 30, 4:02 PM ET
DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate
Press releaseJul 30, 4:02 PM ETBusiness Wire
Dexcom Reports Second Quarter 2026 Financial Results
Press releaseJul 29, 9:12 AM ETPRNewswire
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Press releaseJul 23, 7:00 AM ETBusiness Wire
Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm
NewsJul 22, 5:18 PM ET
DexCom Selected As First Participant For FDA's TEMPO Digital Health Devices Program
Press releaseJul 22, 5:15 PM ETBusiness Wire
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
NewsJul 22, 2:14 PM ET
Dexcom Selected By FDA As First Participant For Technology-Enabled Meaningful Patient Outcomes For Digital Health Devices Pilot
NewsJul 13, 4:46 PM ET
Dexcom Receives Health Canada Authorization For Dexcom G7 15 Day CGM System, Offering 15.5-Day Wear, 8.0% MARD Accuracy, And Fewer Sensor Changes For Canadians With Diabetes
Press releaseJul 13, 4:45 PM ETBusiness Wire
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
Press releaseJul 9, 8:30 AM ETBusiness Wire
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
Press releaseJul 3, 12:27 PM ETPRNewswire
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Press releaseJun 23, 9:00 AM ETBusiness Wire
Dexcom Further Advances Vision of Glucose Biosensing for All
NewsJun 15, 1:02 PM ETVandana Singh
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor
NewsJun 12, 3:44 PM ET
FDA Clears First Over-The-Counter Continuous Glucose Monitor For Children
NewsJun 8, 2:15 PM ETVandana Singh
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes
Press releaseJun 6, 2:45 PM ETBusiness Wire
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
NewsJun 4, 9:11 AM ET
DexCom To Present New Data And Announce Strategic Business Initiatives At American Diabetes Association's Scientific Sessions In New Orleans, June 5-8
Press releaseJun 4, 9:00 AM ETBusiness Wire
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
Press releaseJun 2, 9:30 AM ETBusiness Wire
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
Press releaseMay 26, 9:30 AM ETBusiness Wire
Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
Press releaseMay 18, 7:31 AM ETBusiness Wire
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
NewsMay 15, 1:41 PM ETVandana Singh
Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
NewsMay 15, 12:30 PM ET
Reported May 14, 2026: DexCom To Add Two Independent Directors And Expand Operations And Innovation Committee Following Constructive Engagement With Elliott Investment Management
Press releaseApr 29, 10:30 AM ETPRNewswire
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
Press releaseFeb 4, 8:30 AM ETBusiness Wire
Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management
NewsJun 25, 12:00 PM ET
Price Over Earnings Overview: DexCom
Press releaseAug 20, 6:06 AM ETGlobe Newswire
DXCM STOCK ALERT: Suffer Losses on Your DexCom, Inc. Investment? Investors are Encouraged to Contact BFA Law about its Securities Fraud Class Action Investigation (NASDAQ:DXCM)
Press releaseAug 18, 6:15 AM ETGlobe Newswire
DXCM INVESTMENT NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors that Lost Money are Encouraged to Contact BFA Law about its Investigation (NASDAQ:DXCM)
Press releaseAug 16, 6:17 AM ETGlobe Newswire
DXCM INVESTIGATION ALERT: Has DexCom, Inc. Violated the Federal Securities Laws? Investors are Alerted to Contact BFA Law if You Suffered Losses on Your Investment (NASDAQ:DXCM)
Press releaseAug 14, 7:25 AM ETGlobe Newswire
DXCM FRAUD ALERT: BFA Law is Investigating DexCom, Inc. for Securities Fraud – Contact the Firm if You Suffered Losses on Your Investment (Nasdaq:DXCM)
Press releaseAug 12, 6:11 AM ETGlobe Newswire
DXCM INVESTOR NEWS: DexCom, Inc. Investors that Suffered Losses are Encouraged to Contact BFA Law about a Potential Class Action Lawsuit for Securities Fraud (Nasdaq:DXCM)
Press releaseAug 10, 7:36 AM ETGlobe Newswire
DXCM INVESTOR ALERT: A Securities Fraud Investigation was Initiated Against DexCom, Inc. (Nasdaq:DXCM); Investors that Lost Money are Encouraged to Contact BFA Law
Press releaseAug 8, 6:16 AM ETGlobe Newswire
DXCM STOCK ALERT: Suffer Losses on Your DexCom, Inc. Securities? Contact BFA Law about its Investigation into NASDAQ:DXCM for Securities Fraud
Press releaseAug 6, 7:10 AM ETGlobe Newswire
DXCM FRAUD NOTICE: Lose Money on Your DexCom, Inc. Investment? BFA Law is Investigating the Company for Securities Fraud and Urges You to Contact the Firm (NASDAQ:DXCM)
Press releaseAug 4, 6:52 AM ETGlobe Newswire
DXCM STOCK NOTICE: DexCom, Inc. is being Investigated for Securities Fraud by BFA Law; Shareholders that Lost Money are Urged to Contact the Firm (NASDAQ:DXCM)

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

The Insider Report: The Leaders Have Taken Off

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

Dexcom Appoints Glenn Boehnlein to Board of Directors

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Dexcom Announces Upcoming Conference Presentation

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 Billion

AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday

DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate

Dexcom Reports Second Quarter 2026 Financial Results

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

DexCom Selected As First Participant For FDA's TEMPO Digital Health Devices Program

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

Dexcom Selected By FDA As First Participant For Technology-Enabled Meaningful Patient Outcomes For Digital Health Devices Pilot

Dexcom Receives Health Canada Authorization For Dexcom G7 15 Day CGM System, Offering 15.5-Day Wear, 8.0% MARD Accuracy, And Fewer Sensor Changes For Canadians With Diabetes

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Dexcom Further Advances Vision of Glucose Biosensing for All

Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor

FDA Clears First Over-The-Counter Continuous Glucose Monitor For Children

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

DexCom To Present New Data And Announce Strategic Business Initiatives At American Diabetes Association's Scientific Sessions In New Orleans, June 5-8

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

Diabetes Tech Player DexCom Lays Out 2030 Growth Vision

Reported May 14, 2026: DexCom To Add Two Independent Directors And Expand Operations And Innovation Committee Following Constructive Engagement With Elliott Investment Management

Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management

Price Over Earnings Overview: DexCom

DXCM STOCK ALERT: Suffer Losses on Your DexCom, Inc. Investment? Investors are Encouraged to Contact BFA Law about its Securities Fraud Class Action Investigation (NASDAQ:DXCM)

DXCM INVESTMENT NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors that Lost Money are Encouraged to Contact BFA Law about its Investigation (NASDAQ:DXCM)

DXCM INVESTIGATION ALERT: Has DexCom, Inc. Violated the Federal Securities Laws? Investors are Alerted to Contact BFA Law if You Suffered Losses on Your Investment (NASDAQ:DXCM)

DXCM FRAUD ALERT: BFA Law is Investigating DexCom, Inc. for Securities Fraud – Contact the Firm if You Suffered Losses on Your Investment (Nasdaq:DXCM)

DXCM INVESTOR NEWS: DexCom, Inc. Investors that Suffered Losses are Encouraged to Contact BFA Law about a Potential Class Action Lawsuit for Securities Fraud (Nasdaq:DXCM)

DXCM INVESTOR ALERT: A Securities Fraud Investigation was Initiated Against DexCom, Inc. (Nasdaq:DXCM); Investors that Lost Money are Encouraged to Contact BFA Law

DXCM STOCK ALERT: Suffer Losses on Your DexCom, Inc. Securities? Contact BFA Law about its Investigation into NASDAQ:DXCM for Securities Fraud

DXCM FRAUD NOTICE: Lose Money on Your DexCom, Inc. Investment? BFA Law is Investigating the Company for Securities Fraud and Urges You to Contact the Firm (NASDAQ:DXCM)

DXCM STOCK NOTICE: DexCom, Inc. is being Investigated for Securities Fraud by BFA Law; Shareholders that Lost Money are Urged to Contact the Firm (NASDAQ:DXCM)